ProCE Banner Activity

Dr. Princy Kumar and Dr. Chloe Orkin: Key HIV Studies From CROI 2023


Hear from CCO’s expert faculty members as they present their insights on some of the most clinically relevant new data presented at CROI 2023, including prevention strategies, long-acting therapies, adverse events, second-line therapies, and coinfection.

Released: March 17, 2023

Expiration: March 15, 2024



Orkin Chloe

Orkin Chloe, BA Innere Medizin und Chirurgie, Fellow des Royal College of Medicine

Professorin für HIV
Queen Mary University of London  
Leiterin der Abteilung für HIV-Forschung
Barts Health NHS Trust
The Royal London Hospital
London, Vereinigtes Königreich

Princy N. Kumar

Princy N. Kumar, MD, FIDSA, MACP

Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Tropical Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC


Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc.

ViiV Healthcare

Faculty Disclosure

Princy N. Kumar, MD, FIDSA, MACP: consultant/advisor/speaker: Gilead, Johnson & Johnson, Merck, Theratechnologies, ViiV Healthcare; researcher: American Gene Technologies, Gilead Sciences, GSK, Merck; stock/stock options: Gilead Sciences, GSK, Johnson & Johnson, Merck, Pfizer.

Chloe Orkin, MBChB, FRCP, MD: consultant/advisor/speaker: Gilead Sciences, Janssen, MSD, ViiV Healthcare; researcher: AstraZeneca, Gilead Sciences, Janssen, MSD, ViiV Healthcare.